Relation Therapeutics vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Relation Therapeutics uses its Lab-in-the-Loop AI platform to discover novel drug targets; secured a $1.7B multi-program Novartis collaboration and a $200M+ GSK partnership; raised $26M additional funding from NVIDIA Ventures in December 2025.
About
Relation Therapeutics is a UK-based clinical-stage biotechnology company that integrates artificial intelligence with experimental biology to discover novel therapeutic targets for diseases with significant unmet medical need. Its proprietary Lab-in-the-Loop platform combines machine learning with patient-derived single-cell multi-omics data, functional assays, and human genetics to identify causal genes and validate novel drug targets — moving beyond correlative genomics to experimental confirmation. The company''s initial therapeutic focus is osteoporosis, with additional programs in immunology, metabolic disease, and fibrosis.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.